152 related articles for article (PubMed ID: 2450180)
1. Studies on neurotransmitter markers of the basal ganglia in Pick's disease, with special reference to dopamine reduction.
Kanazawa I; Kwak S; Sasaki H; Muramoto O; Mizutani T; Hori A; Nukina N
J Neurol Sci; 1988 Jan; 83(1):63-74. PubMed ID: 2450180
[TBL] [Abstract][Full Text] [Related]
2. Studies on neurotransmitter markers and striatal neuronal cell density in Huntington's disease and dentatorubropallidoluysian atrophy.
Kanazawa I; Sasaki H; Muramoto O; Matsushita M; Mizutani T; Iwabuchi K; Ikeda T; Takahata N
J Neurol Sci; 1985 Sep; 70(2):151-65. PubMed ID: 2865338
[TBL] [Abstract][Full Text] [Related]
3. Neurochemical observations in a case of Pick's disease.
Yates CM; Simpson J; Maloney AF; Gordon A
J Neurol Sci; 1980 Nov; 48(2):257-63. PubMed ID: 7431041
[TBL] [Abstract][Full Text] [Related]
4. Neurochemical substrates of rigidity and chorea in Huntington's disease.
Storey E; Beal MF
Brain; 1993 Oct; 116 ( Pt 5)():1201-22. PubMed ID: 7693298
[TBL] [Abstract][Full Text] [Related]
5. Distribution of basal ganglia lesions in generalized variant of Pick's disease: a clinicopathological study of four autopsy cases.
Tsuchiya K; Ishizu H; Nakano I; Kita Y; Sawabe M; Haga C; Kuyama K; Nishinaka T; Oyanagi K; Ikeda K; Kuroda S
Acta Neuropathol; 2001 Nov; 102(5):441-8. PubMed ID: 11699556
[TBL] [Abstract][Full Text] [Related]
6. A post-mortem comparison of the cortical cholinergic system in Alzheimer's disease and Pick's disease.
Wood PL; Etienne P; Lal S; Nair NP; Finlayson MH; Gauthier S; Palo J; Haltia M; Paetau A; Bird ED
J Neurol Sci; 1983 Dec; 62(1-3):211-7. PubMed ID: 6142096
[TBL] [Abstract][Full Text] [Related]
7. Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue.
Spokes EG
Brain; 1980 Mar; 103(1):179-210. PubMed ID: 6102490
[TBL] [Abstract][Full Text] [Related]
8. Striatal dopaminergic loss without parkinsonism in a case of corticobasal degeneration.
Marshall EF; Perry RH; Perry EK; Piggott MA; Thompson P; Jaros E; Burn DJ
Acta Neurol Scand; 1997 May; 95(5):287-92. PubMed ID: 9188904
[TBL] [Abstract][Full Text] [Related]
9. Topographic projections of substance P and GABA pathways in the striato- and pallido-nigral system: a biochemical and immunohistochemical study.
Jessell TM; Emson PC; Paxinos G; Cuello AC
Brain Res; 1978 Sep; 152(3):487-98. PubMed ID: 356929
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characterization of Pick's disease versus frontotemporal lobar degeneration with ubiquitin/TDP-43-positive inclusions.
Yokota O; Tsuchiya K; Arai T; Yagishita S; Matsubara O; Mochizuki A; Tamaoka A; Kawamura M; Yoshida H; Terada S; Ishizu H; Kuroda S; Akiyama H
Acta Neuropathol; 2009 Apr; 117(4):429-44. PubMed ID: 19194716
[TBL] [Abstract][Full Text] [Related]
11. Altered serotonergic and cholinergic synaptic markers in Pick's disease.
Sparks DL; Markesbery WR
Arch Neurol; 1991 Aug; 48(8):796-9. PubMed ID: 1898253
[TBL] [Abstract][Full Text] [Related]
12. [Pick's disease. A special type of pathological aging of the brain].
Seitelberger F
Aktuelle Gerontol; 1982 Nov; 12(6):200-5. PubMed ID: 6130712
[TBL] [Abstract][Full Text] [Related]
13. Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation.
Lindefors N; Brodin E; Tossman U; Segovia J; Ungerstedt U
Exp Brain Res; 1989; 74(3):527-34. PubMed ID: 2468514
[TBL] [Abstract][Full Text] [Related]
14. Basal ganglia lesions in 'Pick complex': a topographic neuropathological study of 19 autopsy cases.
Tsuchiya K; Ikeda K
Neuropathology; 2002 Dec; 22(4):323-36. PubMed ID: 12564774
[TBL] [Abstract][Full Text] [Related]
15. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.
Glass M; Dragunow M; Faull RL
Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533
[TBL] [Abstract][Full Text] [Related]
16. Striatopallidonigral degeneration in Pick's disease: a clinicopathological study of 41 cases.
Kosaka K; Ikeda K; Kobayashi K; Mehraein P
J Neurol; 1991 Jun; 238(3):151-60. PubMed ID: 1869891
[TBL] [Abstract][Full Text] [Related]
17. Reduction in basal ganglia and substantia nigra substance P levels in Huntington's disease.
Buck SH; Burks TF; Brown MR; Yamamura HI
Brain Res; 1981 Mar; 209(2):464-9. PubMed ID: 6164436
[TBL] [Abstract][Full Text] [Related]
18. Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease.
Araujo DM; Hilt DC
Neuroscience; 1997 Dec; 81(4):1099-110. PubMed ID: 9330371
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography and histopathology in Pick's disease.
Kamo H; McGeer PL; Harrop R; McGeer EG; Calne DB; Martin WR; Pate BD
Neurology; 1987 Mar; 37(3):439-45. PubMed ID: 3493451
[TBL] [Abstract][Full Text] [Related]
20. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
Betarbet R; Greenamyre JT
Exp Neurol; 2004 Oct; 189(2):393-403. PubMed ID: 15380489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
